Neogenomics Inc. (NASDAQ: NEO) on Tuesday, soared 5.51% from the previous trading day, before settling in for the closing price of $13.42. Within the past 52 weeks, NEO’s price has moved between $11.03 and $21.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.35% over the past five years. The company achieved an average annual earnings per share of 96.81%. With a float of $126.18 million, this company’s outstanding shares have now reached $127.37 million.
Let’s look at the performance matrix of the company that is accounted for 2100 employees.
Neogenomics Inc. (NEO) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Neogenomics Inc. is 1.16%, while institutional ownership is 99.20%. The most recent insider transaction that took place on Mar 04 ’24, was worth 97,579. In this transaction Director of this company sold 6,112 shares at a rate of $15.97, taking the stock ownership to the 50,062 shares. Before that another transaction happened on Feb 15 ’24, when Company’s General Counsel sold 2,587 for $14.96, making the entire transaction worth $38,713. This insider now owns 34,866 shares in total.
Neogenomics Inc. (NEO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 96.81% per share during the next fiscal year.
Neogenomics Inc. (NASDAQ: NEO) Trading Performance Indicators
Neogenomics Inc. (NEO) is currently performing well based on its current performance indicators. A quick ratio of 5.95 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Neogenomics Inc. (NEO)
Neogenomics Inc. (NASDAQ: NEO) saw its 5-day average volume 0.78 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 23.97%. Additionally, its Average True Range was 0.62.
During the past 100 days, Neogenomics Inc.’s (NEO) raw stochastic average was set at 10.41%, which indicates a significant decrease from 36.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.38% in the past 14 days, which was lower than the 56.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.07, while its 200-day Moving Average is $15.46. Nevertheless, the first resistance level for the watch stands at $14.62 in the near term. At $15.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.69. If the price goes on to break the first support level at $13.55, it is likely to go to the next support level at $12.94. Assuming the price breaks the second support level, the third support level stands at $12.48.
Neogenomics Inc. (NASDAQ: NEO) Key Stats
Market capitalization of the company is 1.81 billion based on 127,666K outstanding shares. Right now, sales total 591,640 K and income totals -87,970 K. The company made 155,550 K in profit during its latest quarter, and -14,330 K in sales during its previous quarter.
